Biosense Webster Indication

Tailor your approach and deliver lasting impact with the CARTO® 3 System and THERMOCOOL SMARTTOUCH® SF Catheter.1,a

grandma and grandpa

In the prospective, multicenter PRECEPT study, 80% of persistent AF patients experienced clinical success at 15 months following radiofrequency catheter ablation with the THERMOCOOL SMARTTOUCH® SF Catheter.1,2,a

Webinar

Workflow Examples

Watch this systematic approach to persistent AF

Clinical Evidence

Clinical Evidence

Learn more about the PRECEPT clinical study

Key Takeaways

Key Takeaways

Download the fact sheet

References

1. Mansour M, Calkins H, Osorio J, et al. Persistent atrial fibrillation ablation with contact force sensing catheter: The prospective multicenter PRECEPT trial. JACC Clin Electrophysiol. 2020;6(8):958-969.
2. PRECEPT IDE G140102.

Abbreviations and Footnotes

AF, atrial fibrillation.

a In a prospective, multicenter study (PRECEPT, n=333), where clinical success is defined as freedom from documented symptomatic AF/AT/AFL recurrence.

The THERMOCOOL SMARTOUCH® SF Catheter is indicated for drug refractory recurrent symptomatic persistent atrial fibrillation (AF) (continuous AF >7 days but <1 year), refractory or intolerant to at least 1 Class I or III AAD, when used with the CARTO® 3 System.
Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, warnings and precautions. Caution: US law restricts this device to sale by or on the order of a physician.

153589-200921